350 related articles for article (PubMed ID: 12663051)
1. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
Wang Y; Zhao R; Goldman ID
Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
[TBL] [Abstract][Full Text] [Related]
2. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
Zhao R; Babani S; Gao F; Liu L; Goldman ID
Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
[TBL] [Abstract][Full Text] [Related]
4. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
5. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
6. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
7. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line.
Chattopadhyay S; Zhao R; Krupenko SA; Krupenko N; Goldman ID
Mol Cancer Ther; 2006 Feb; 5(2):438-49. PubMed ID: 16505119
[TBL] [Abstract][Full Text] [Related]
8. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells.
Zhao R; Gao F; Goldman ID
Biochem Pharmacol; 2001 Apr; 61(7):857-65. PubMed ID: 11274972
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
Zhao R; Gao F; Babani S; Goldman ID
Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
[TBL] [Abstract][Full Text] [Related]
10. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
[TBL] [Abstract][Full Text] [Related]
11. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
[TBL] [Abstract][Full Text] [Related]
12. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
[TBL] [Abstract][Full Text] [Related]
13. Molecular, biochemical, and cellular pharmacology of pemetrexed.
Goldman ID; Zhao R
Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
[TBL] [Abstract][Full Text] [Related]
14. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
15. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
Kobayashi H; Takemura Y; Ohnuma T
Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
[TBL] [Abstract][Full Text] [Related]
16. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ
Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
18. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.
Jansen G; Mauritz R; Drori S; Sprecher H; Kathmann I; Bunni M; Priest DG; Noordhuis P; Schornagel JH; Pinedo HM; Peters GJ; Assaraf YG
J Biol Chem; 1998 Nov; 273(46):30189-98. PubMed ID: 9804775
[TBL] [Abstract][Full Text] [Related]
19. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
Zhao R; Hanscom M; Chattopadhyay S; Goldman ID
Cancer Res; 2004 May; 64(9):3313-9. PubMed ID: 15126375
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
